

# The Hypoglycaemia-Hyperglycaemia Minimizer System in the Management of Type 1 Diabetes

Brian L Levy, Thomas W McCann, Jr and Daniel A Finan

*Animas Corporation, Wayne, USA*

DOI: <http://doi.org/10.17925/EE.2016.12.01.18>

## Abstract

Living with type 1 diabetes (T1D) presents many challenges in terms of daily living. Insulin users need to frequently monitor their blood glucose levels and take multiple injections per day and/or multiple boluses through an insulin infusion pump, with the consequences of failing to match the insulin dose to the body's needs resulting in hypoglycaemia and hyperglycaemia. The former can result in seizures, coma and even death; the latter can have both acute and long-term health implications. Many patients with T1D also fail to meet their treatment goals. In order to reduce the burdens of self-administering insulin, and improve efficacy and safety, there is a need to at least partially remove the patient from the loop via a closed-loop 'artificial pancreas' system. The Hypoglycaemia-Hyperglycaemia Minimizer (HHM) System, comprising a continuous, subcutaneous insulin infusion pump, continuous glucose monitor (CGM) and closed-loop insulin dosing algorithm, is able to predict changes in blood glucose and adjust insulin delivery accordingly to help keep the patient at normal glucose levels. Early clinical data indicate that this system is feasible, effective and safe, and has the potential to dramatically improve the therapeutic outcomes and quality of life for people with T1D.

## Keywords

Hypoglycaemia-Hyperglycaemia Minimizer System, type 1 diabetes, artificial pancreas

**Disclosure:** Brian L Levy, Thomas W McCann, Jr and Daniel A Finan are employees of Animas Corporation.

**Acknowledgments:** Medical writing support was provided by Katrina Mountfort at Touch Medical Media, funded by Animas Corporation.

**Open Access:** This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit. © The Author(s) 2016

**Received:** 16 December 2015 **Accepted:** 25 January 2016 **Citation:** *European Endocrinology*, 2016;12(1):18–23

**Correspondence:** Daniel A Finan, Animas Corporation, 965 Chesterbrook Blvd, Wayne, PA 19087, US E: DFinan@its.jnj.com

**Support:** The publication of this article was supported by the Animas Corporation. The views and opinions expressed in the article are those of the authors and not necessarily those of the Animas Corporation.

Type 1 diabetes (T1D) is a lifelong condition that results from autoimmune destruction of insulin-secreting beta cells, resulting in an absence of insulin production. In the US, it is estimated that 29.1 million people have diabetes,<sup>1</sup> with T1D accounting for 5–10% of all cases. Furthermore, its incidence is increasing, particularly among children under the age of 15.<sup>2</sup> A doubling of new cases of T1D in European children younger than five years has been predicted between 2005 and 2020, with a 70% rise in children younger than 15 years.<sup>3</sup> Optimal glycaemic control is essential in people living with T1D; intensive treatment of T1D has been associated with delayed onset and slowed progression of numerous complications, including diabetic retinopathy, nephropathy and neuropathy.<sup>4</sup>

Management of T1D involves multiple daily injections of insulin or use of an insulin pump, both of which require the user to actively track glucose and calculate the needed insulin dose. There is also a significant time lag between when a dose is administered and when it takes effect. Other therapies, including immunotherapy and islet cell transplantation, have been investigated, but with limited success.<sup>5,6</sup> There is therefore a need for an automated system that removes the patient from the loop: a closed-loop system.<sup>7</sup> This article discusses the potential clinical benefits of closed-loop systems, with a focus on the Hypoglycaemia-Hyperglycaemia Minimizer System (HHM System; Animas Corporation, West Chester, PA, US).

## The Treatment Burden of Living with Type 1 Diabetes

Exogenous insulin therapy is not subject to the usual physiological feedback mechanisms so may induce hypoglycaemia.<sup>8</sup> The risk of hypoglycaemia limits the efficacy of insulin therapy; the average patient suffers two episodes of symptomatic hypoglycaemia per week and one severe episode per year.<sup>4,8–10</sup> Severe hypoglycaemic episodes often occur during sleep.<sup>11</sup> These episodes, termed nocturnal hypoglycaemia, can cause convulsions and coma,<sup>12</sup> and can be a rare cause of death in individuals with T1D.<sup>13</sup> The fear of hypoglycaemia has been associated with decreased quality of life in children with T1D<sup>14</sup> and their parents.<sup>15</sup> Fear of hypoglycaemia can also result in avoidance of activities beneficial to health, such as exercise.<sup>16</sup>

In addition, insulin therapy is associated with poor compliance. In the US, children with T1D often do not meet their treatment goals in terms of glycated haemoglobin (HbA<sub>1c</sub>) values.<sup>17</sup> Several factors contribute to this failure, including difficulty in correctly estimating the amount of carbohydrates in a meal, missed meal boluses and anxiety about hypoglycaemia resulting in under-treatment. Poor glycaemic control may affect cognitive development in children with T1D.<sup>18</sup> In addition, short-term variation in glucose levels can have an effect on complications of T1D.<sup>19</sup> It is well-known that compliance is difficult to achieve with complicated treatment regimens.

Insulin pump therapy has been associated with improvements in glycaemic control in adults and children with T1D.<sup>20</sup> Continuous subcutaneous insulin infusion (CSII) therapy is conducted using a durable or patch pump that delivers insulin continuously from a cartridge reservoir via a subcutaneously inserted cannula. The pump can be programmed to deliver varied basal rates of insulin throughout the day, with additional boluses of insulin delivered via self-administration at meal times. Although all pump models can deliver insulin continuously, a technical evaluation conducted on durable pumps such as the OneTouch® Ping® (Animas Corporation, West Chester, PA, US), Accu-Chek® Combo (Roche Diagnostics, Indianapolis, IN, US) and MiniMed Paradigm® Revel™/Veo™ (Medtronic, Northridge, CA, US), and one patch pump, such as the Insulet OmniPod, showed significant differences in single-dose accuracy performance. At a 0.5 U/hr basal rate over 20 hours, durable pumps delivering in 3-minute intervals showed better single-dose accuracy than the patch pump delivering in 6-minute intervals. Among the durable pumps, the OneTouch Ping demonstrated significantly better accuracy.

Continuous glucose monitoring (CGM) in conjunction with home blood glucose monitoring can improve glycaemic control<sup>21</sup> and reduce hypoglycaemia<sup>22</sup> in adult patients with T1D. CGM has also been associated with benefits in quality of life (QoL), which are correlated with satisfaction with device accuracy and usability and trust in one's ability to use CGM data.<sup>23</sup> Widespread adoption of CGM has been constrained by its cost and limited reimbursement in healthcare schemes,<sup>24</sup> but a growing body of evidence supports its use,<sup>21,25</sup> resulting in expert opinions that reimbursement is justified in certain patient groups.<sup>26</sup>

In order to be used within a closed-loop system, good continuous glucose sensor performance is crucial. However, continuous glucose sensors have been associated with a failure to detect more than half of hypoglycaemic events as well as giving false alarms of impending hypoglycaemia.<sup>27</sup> While standards for accuracy exist (International Organization for Standardization 15197:2013), there is no consensus on a standard method for assessing accuracy. Studies do not always assess CGM across all glycaemic ranges.<sup>27,28</sup> A comparison of the two most widely used sensor systems, the G4® platinum (Dexcom, San Diego, CA, US) and the Paradigm VEO Enlite™ (Medtronic, Northridge, CA, US) found that the G4 sensor was significantly more accurate than the Enlite system, and that both were less accurate in the hypoglycaemic range.<sup>29</sup> In another study the Dexcom G4 sensor showed greater overall accuracy than the Enlite system both overall and for glucose levels in the hypoglycaemic range. In addition, patient satisfaction was higher using the G4 system than the Enlite.<sup>30</sup> A further head-to-head comparison of three CGMs (FreeStyle Navigator, [Abbott Diabetes Care, Alameda, CA, US]; G4 Platinum and Enlite) in adult and paediatric patients with T1D under closed-loop blood glucose control demonstrated that the G4 was the most accurate and precise of the devices studied, followed closely by the Navigator, and both were markedly more accurate and precise than the Enlite sensor.<sup>31</sup>

Perhaps the most important benefit of CGM is avoidance of hypoglycaemic events. Hypoglycaemia can also be avoided by aiming for a slightly higher glucose target: a set point of 140 mg/dL could significantly reduce the risk of severe hypoglycaemia with an acceptable increase in time spent at higher glucose range.<sup>32</sup>

However, CGM systems have limitations as they still require considerable patient participation in terms of glucose testing, counting carbohydrates and estimating insulin dosages to be administered. This is feasible, if

demanding, during the day, but not at night, when many hypoglycaemic episodes occur. There remains a need for control algorithms that adjust insulin delivery according to daily food intake and activity.

### The Concept of a Closed-loop Delivery System

There remains a need to 'close the loop' between the glucose sensor and insulin pump. The aim of such a closed-loop delivery system is to at least partially automate insulin delivery based on CGM so as to obtain improved glucose control. The first closed loop system was developed over 40 years ago. However, this device was used only for academic purposes.<sup>33</sup> Around 20 years ago, large bedside systems using intravenous blood sampling and intravenous insulin infusion became available in intensive care settings in Japan, but their use was infrequent.<sup>34</sup> Transition of such systems to routine clinical use requires accurate, minimally invasive CGM technology integrated with subcutaneous insulin delivery devices – and physiologically informed algorithms to connect the two.

Recent systems use a control algorithm, i.e. software stored on a pump, smartphone or other device, to regulate the insulin delivery based on real-time glucose levels obtained by the sensor. The development of a closed-loop system has faced many difficulties including accuracy of CGM, the physiological time lags involved in the diffusion of the glucose from the plasma to the interstitial fluid when glucose is changing rapidly and delays in both the absorption of insulin and its onset of action after a subcutaneous injection.<sup>7</sup>

A number of systems are currently undergoing clinical investigation. A growing body of data indicates that these are safe and feasible in daily living situations and result in improved glycaemic control (see *Table 1*).<sup>35–43</sup>

Industry's first foray into commercially available closed-loop technology was the MiniMed® 530G (Medtronic, Northridge, CA, US). In brief, the algorithm in such a device uses simple, straightforward logic to suspend insulin delivery when a breach of a low threshold is registered by the integrated CGM, with an associated patient notification. The suspension continues until that confirmation is acknowledged, or when two hours have elapsed, whichever comes first.<sup>44</sup> Such systems have been shown to be effective in improving glycaemic control and reducing hypoglycaemia<sup>45</sup> in patients with T1D. Other clinical development studies sponsored by Medtronic are in progress, investigating more sophisticated algorithms.<sup>46</sup> The predictive low glucose suspend system represents an advance from the glucose suspend device, and halts insulin delivery overnight with the aim of preventing nocturnal hypoglycaemia.<sup>47–49</sup> Such systems have also been evaluated for use during exercise, with positive results.<sup>50</sup>

Studies have found that attitudes towards closed-loop systems are positive among patients<sup>51</sup> and caregivers of children with T1D.<sup>52</sup> Night-time blood glucose control is the biggest concern for parents and a small study (n=19) indicated that 90% of parents trusted an algorithm to control overnight insulin delivery.<sup>52</sup>

### The Hypoglycaemia–Hyperglycaemia Minimizer System

In 2006, the Juvenile Diabetes Research Foundation (JDRF) launched the artificial pancreas programme, which involved direct funding and collaborations with academic institutions, research centres and industry in the US and Europe. Many leading diabetes device manufacturers have participated in this project, developing CGM systems and pumps with enhanced capability for closed-loop use.

**Table 1: Clinical Studies Investigating the Feasibility of Closed-loop Systems**

Study Design	Key Findings	Reference
Phase II RCT, n=19, age 5–18 years, compared standard insulin infusion and CL delivery; CL delivery after rapidly and slowly absorbed meals; and CL delivery and standard treatment after exercise	CL increased time in the target range (60% versus 40%; p=0.0022) and reduced time of glucose levels $\leq$ 70 mg/dL (2.1% [0.0–10.0] versus 4.1% [0.0–42.0]; p=0.0304)	Horkova et al., 2010 <sup>57</sup>
RCT comparing CL with standard insulin infusion, n=10, aged <7 years, inpatient research centre	CL delivery increased nocturnal time glucose levels were in target for closed- versus open-loop therapy, although not significant (5.3 versus 3.2 h; p=0.12). Significant improvement in time spent >300 mg/dL overnight with CL therapy (0.18 versus 1.3 h; p=0.035). CL delivery returned pre-lunch blood glucose closer to target (189 versus 273 mg/dL on open loop; p=0.009)	Dauber et al., 2013 <sup>35</sup>
RCT, n=12, mean age 15. CL basal insulin delivery or conventional pump therapy for 36 h. During CL insulin delivery, pump basal rates were adjusted every 15 min according to a model predictive control algorithm	CL basal insulin delivery increased time glucose levels were in target range (84% [78–88%] versus 49% [26–79%]; p=0.02) and reduced mean plasma glucose levels (128 [19] versus 165 [55] mg/dL; p=0.02). Glucose levels were in target range 100% of the time on 17 of 24 nights during CL insulin delivery. Hypoglycaemia occurred on 10 occasions during control visits and 9 occasions during CL delivery (5 episodes were exercise related, and 4 occurred within 2.5 h of prandial bolus)	Elleri et al., 2013 <sup>36</sup>
RCT, n=12, mean age 15.9 years, compared CL therapy with meal announcement with conventional pump therapy over two 24-h stays at an inpatient research centre	Plasma glucose levels were in the target range of 3.9–10 mmol/l for 74% (55–86%) of the time during CL therapy with meal announcement and for 62% (49–75%) of the time during conventional therapy (p=0.26). Median time spent with glucose levels >10 mmol/l (23% [13–39%] versus 27% [10–50%]; p=0.88) or < 3.9 mmol/l (1% [0–4%] versus 5 [1– 10%]; p=0.24)	Elleri et al., 2014 <sup>38</sup>
Feasibility study, HHM, n=13 adults, 20 h	Participants spent a mean $\pm$ (SD) of 0.2 $\pm$ 0.5% of the CL control time at glucose levels <70 mg/dL, including 0.3 $\pm$ 0.9% for the overnight period. The mean $\pm$ SD glucose based on for all participants was 164.5 $\pm$ 23.5 mg/dL. The algorithm recommended supplemental carbohydrate administrations, and there were no severe hypoglycaemia or diabetic ketoacidosis	Finan et al., 2014 <sup>53</sup>
Feasibility study, n=20, adults, clinical research centre, 26 h	The aggressive setting of the algorithm resulted in the least time spent at levels >180 mg/dL, and the most time spent between 70–180 mg/dL. There was no severe hyperglycaemia, diabetic ketoacidosis or severe hypoglycaemia for any of the aggressiveness values investigated	Finan et al., 2014 <sup>54</sup>
Feasibility study, n=16, age 12–18. For 3 weeks, overnight insulin delivery was directed by a CL system, and on another 3-week period sensor-augmented therapy was applied.	CL was constantly applied over at least 4 h on 269 nights (80%); sensor data were collected over at least 4 h on 282 control nights (84%). CL increased time spent with glucose in target by a median 15% (-9 to 43; p<0.001). Mean overnight glucose was reduced by a mean 14 (SD 58) mg/dL (p<0.001). Nights with glucose <63 mg/dL for at least 20 min were less frequent during CL (10 versus 17%; p=0.01). Despite lower total daily insulin doses by a median 2.3 (interquartile range -4.7 to 9.3) units (p=0.009), overall 24-h glucose was reduced by a mean 9 (SD 41) mg/dL (p=0.006) during CL	Horkova et al., 2014 <sup>39</sup>
Multicentre RCT, n=25, age >18, 4 weeks of overnight CL insulin delivery (using a model-predictive control algorithm to direct insulin delivery), then 4 weeks of insulin pump therapy (in which participants used real-time display of continuous glucose monitoring independent of their pumps as control), or vice versa.	CL was used over a median of 8.3 h (IQR 6.0–9.6) on 555 (86%) of 644 nights. The proportion of time when overnight glucose was in target range was significantly higher during the CL period compared with during the control period (mean difference between groups 13.5%, 95% CI 7.3–19.7; p=0.0002). No severe hypoglycaemic episodes during the control period compared with two episodes during the CL period: these episodes were not related to CL algorithm instructions	Thabit et al., 2014 <sup>42</sup>
Two multicentre RCTs under free-living home conditions, we compared CL insulin delivery with sensor-augmented pump therapy in 58 patients with type 1 diabetes. The CL system was used day and night by 33 adults and overnight by 25 children and adolescents. Participants used the CL system for a 12-week period and sensor-augmented pump therapy (control) for a similar period	Glucose levels were in target range for 11% (95% CI 8.1–13.8) longer with the CL than with control (p<0.001). Mean glucose level was lower during CL than during control phase (difference, -11 mg per deciliter; 95% CI -17 to -6; p<0.001), as were the AUC for the period when glucose level was < 63 mg/dL (39% lower; 95% CI 24 to 51; p<0.001) and the mean glycated haemoglobin level (difference, -0.3%; 95% CI -0.5 to -0.1; p=0.002). Among children and adolescents, the proportion of time with the night-time glucose level in the target range was higher during CL than during the control phase (by 24.7%; 95% CI 20.6 to 28.7; p<0.001), and the mean night-time glucose level was lower (difference, -29 mg/dL; 95% CI -39 to -20; p<0.001). Three severe hypoglycaemic episodes occurred during the CL phase system was not in use	Thabit, 2015 <sup>43</sup>

AUC = area under curve; CI = confidence interval; CL = closed-loop; HCL = hybrid closed-loop; HHM = Hypoglycaemia-Hyperglycaemia Minimizer; IQR = interquartile range; RCT = randomised controlled trial.

The HHM System has been developed by Animas Corporation in collaboration with the JDRF, and is based on a closed-loop technology that it is designed to predict potential hypo- or hyperglycaemic excursions, and proactively decrease or increase (respectively) insulin

infusion in order to mitigate, if not avoid, the excursions. The System is illustrated in *Figures 1* and *2*, and comprises a CGM (Dexcom, Inc., San Diego, CA, US), insulin pump (Animas Corporation, West Chester, PA, US), and control algorithm. The main component of the HHM System is


the control algorithm, which calculates the optimal amount of insulin to deliver to the patient based on CGM trends, previously infused insulin and model predictions. The algorithm determines how much insulin is needed to result in the optimal glucose trajectory for the near future, and transmits this information to the insulin pump for delivery. This process is repeated every five minutes, each time a new CGM datum is received.

### Feasibility Studies Investigating the Hypoglycaemia-Hyperglycaemia Minimizer System

Three clinical research centre (CRC)-based studies have investigated the feasibility of the HHM System. One of these studies was conducted in 13 adults with T1D, who underwent closed-loop control lasting approximately 20 hours, including an overnight period and two meals. The predictive HHM System decreased insulin infusion rates below the participants' preset basal rates ahead of excursions below the prespecified target zone (CGM <90 mg/dL), and delivered 80.4% less basal insulin during such excursions. Similarly, the HHM System increased infusion rates when a breach of the upper threshold (CGM >140 mg/dL) was predicted, and delivered 39.9% more insulin than basal during these excursions. Subjects spent a mean  $\pm$  standard deviation (SD) of  $0.2 \pm 0.5\%$  of the study at glucose levels <70 mg/dL, including  $0.3 \pm 0.9\%$  during the overnight period. The mean glucose level across the entire study period was  $164.5 \pm 23.5$  mg/dL. The HHM was able to administer insulin safely and, on nine occasions, recommended the administration of carbohydrate in the form of which was 15 g of carbohydrate as juice or glucose tablets. During the study, there were no instances of severe hypoglycaemia or diabetic ketoacidosis.<sup>53</sup>


A second feasibility study was conducted in 20 adults with T1D to assess the predictive capability of the HHM System in terms of mitigating hypoglycaemic excursions, defined as a breach of the 70 mg/dL threshold, by CGM. First, the potential of the system to prevent hypoglycaemic excursions was investigated by quantifying the frequency of times that the glucose level assessed by CGM reached a local nadir of between 70–90 mg/dL (see Figure 3), indicating that it was potentially due to the algorithm's hypoglycaemia-mitigating, insulin-reducing action that the CGM began to rise following its nadir. In order to isolate the effects of the algorithm, the glucose-increasing effects of carbohydrate meals were excluded in the calculation of this metric, by ignoring data received during the hour following each meal. Second, the capability to proactively mitigate hypoglycaemic excursions was quantified as the average lead time, before a breach of the CGM 70 mg/dL threshold, that the algorithm reduced or suspended insulin delivery. In addition, the amount of insulin withheld during this period was assessed. Thirdly, the ability of the algorithm to warn of imminent hypoglycaemic events was quantified by the average lead time, before the breach, that the alarm was triggered. Results showed that a CGM nadir between 70 and 90 occurred an average of 1.75 times per subject per day. On average, over 24 h, subjects spent 80–90% the time within the normal glycaemic range. Additionally, fewer than half of the subjects had blood glucose values less than 70 mg/dL during the overnight period. It must be noted, however, in this small feasibility study, that it cannot be known with what frequency the actions of the algorithm were directly responsible for avoiding hypoglycaemic events. The algorithm reduced insulin delivery for an average of 39 minutes prior to breaches of the CGM 70 mg/dL threshold, accounting for an average of 0.5 U of insulin not delivered to the participant, relative to their corresponding basal rates. The algorithm delivered warnings of imminent hypoglycaemia on average 7.1 minutes before such

### Figure 1: Schematic Diagram Showing the Mechanism of Action of the Hypoglycaemia-Hyperglycaemia Minimizer System



CGM = Continuous glucose monitoring; HHM = Hypoglycaemia-Hyperglycaemia Minimizer.

### Figure 2: Setup for Hypoglycaemia-Hyperglycaemia Minimizer System Feasibility Studies




breaches. The investigators concluded that the HHM System reduced insulin delivery and triggered warnings before the CGM breached the low glucose threshold.

This study also evaluated the 'aggressiveness factor', which refers to the speed and magnitude at which the control algorithm adjusts insulin infusion in response to changing CGM measurements (see Figure 4). Enrolment criteria were current use of an insulin infusion pump with rapid-acting insulin, and a HbA<sub>1c</sub> level <10%. Participants were assigned to conservative, medium and aggressive values. Time spent within the normal glycaemic range was highest using the aggressive setting.<sup>54,55</sup>

In a third study, 12 adults with T1D were studied for approximately 24 hours. The purpose of this study was to isolate the hypoglycaemia minimisation aspect of the HHM System. As the aggressiveness setting was increased from 'conservative' to 'medium' to 'aggressive', the controller recommended less insulin (-3.3% versus -14.4% versus -19.5% relative to basal) with a higher frequency (5.3% versus 14.4% versus 20.3%) during the critical times when the CGM reading was decreasing and in the range 90–120 mg/dL. The most aggressive setting resulted in the least time spent at low blood glucose levels (<70 mg/dL) and the most time spent within the normal glycaemic range (70–180 mg/dL), particularly in the overnight period. Hyperglycaemia,

**Figure 3: Example of a Potential Prevention of a Hypoglycaemic Excursion by the Hypoglycaemia-Hyperglycaemia Minimizer System**



Upper graph: Continuous glucose monitoring (CGM) curve shown with the 70–90 mg/dL range. Lower graph: Hypoglycaemia-Hyperglycaemia Minimizer (HHM) System's insulin delivery (bars) shown relative to the current basal rate (black line). This participant's CGM was trending downward when the HHM System effectively suspended insulin delivery. Subsequently, the CGM reached a nadir of 82 mg/dL and began to rise. Source: Finan et al., 2013.<sup>55</sup>

diabetic ketoacidosis or severe hypoglycaemia were not observed at any of the aggressiveness values.<sup>56</sup>


## Discussion

T1D is a chronic condition that can currently only be well managed with constant vigilance, placing a huge burden on patients with T1D and their families. It is hoped that the development of closed-loop systems may result in significant improvements to the quality of life of patients with T1D.

While current closed-loop technology for artificial pancreas applications has matured to the point of commercial viability, there remain a number of scientific and technological limitations in such systems. Such limitations include the pharmacodynamic and pharmacokinetic delays associated with subcutaneous insulin absorption and action; the infeasibility of automatically measuring carbohydrate intake; the disparate patterns of carbohydrate absorption, which varies based on a number of factors such as meal composition – and therefore the inability to accurately model the effects of meals on blood glucose; and the unavailability or nascence of biometric sensors that may inform the control algorithm.

At least some of these barriers to optimal diabetes control may soon be broken down by developments in tangential scientific fields. For

**Figure 4: Mean Glucose Levels of Patients using the Hypoglycaemia-Hyperglycaemia Minimizer System for 24 Hours**



Mean Glucose Levels,  $\pm$  1 Standard Deviation (SD), of Patients using the Hypoglycaemia-Hyperglycaemia Minimizer System for 24 Hours CGM = Continuous glucose monitoring. Adapted from Finan et al., 2014.<sup>54</sup>

example, the formulations of faster-acting insulins may open the door to fully automated meal-time control; continued improvements in the accuracy and reliability of CGM systems may alleviate the burden, at least in part, of blood glucose self-monitoring; the development and commercialisation of med-tech devices able to measure biometrics or surrogates thereof – such as physiological stress and energy expenditure – may help realise a more holistic, robust control algorithm. Future algorithms and systems have a great deal of opportunity in the years ahead to further improve the lives of people with T1D.

The HHM System is a predictive system designed to mitigate, if not avoid completely, hypo- and hyperglycaemic excursions. The superior accuracy and reliability of its CGM sensor and insulin pump are well established. The HHM System has shown promising results in feasibility studies, enabling patients to stay within the designated normal glucose range for up to 90% of the time during a 24-h period. The authors acknowledge the (unavoidable) caveats of these CRC-based studies, namely, the artificial and sedentary environment in which the studies were performed. Nonetheless, the system demonstrated, through its controller actions, the potential to minimise, if not avert entirely, some hypo- and hyperglycaemic excursions. A pivotal study is planned in a larger patient population in ambulatory ('free-living') conditions that will investigate the safety and efficacy of the system, including the final controller configuration and human factors considerations. ■

- CDC, 2014 National Diabetes Statistics Report. Available at: <http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html> (accessed 22 October 2015).
- Hummel K, McFann KK, Realsen J, et al., The increasing onset of type 1 diabetes in children, *J Pediatr*, 2012;161:652–7 e1.
- Patterson CC, Dahlquist GG, Gyurus E, et al., Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study, *Lancet*, 2009;373:2027–33.
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group, *N Engl J Med*, 1993;329:977–86.
- Ryan EA, Paty BW, Senior PA, et al., Five-year follow-up after clinical islet transplantation, *Diabetes*, 2005;54:2060–9.
- Rigby MR, Ehlers MR, Targeted immune interventions for type 1 diabetes: not as easy as it looks!, *Curr Opin Endocrinol Diabetes Obes*, 2014;21:271–8.
- Aye T, Block J, Buckingham B, Toward closing the loop: an update on insulin pumps and continuous glucose monitoring systems, *Endocrinol Metab Clin North Am*, 2010;39:609–24.
- Frier BM, The incidence and impact of hypoglycaemia in type 1 and type 2 diabetes, *International Diabetes Monitor*, 2009;21:210–8.
- Group UKHS, Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration, *Diabetologia*, 2007;50:1140–7.
- Cryer PE, The barrier of hypoglycaemia in diabetes, *Diabetes*, 2008;57:3169–76.
- Banarer S, Cryer PE, Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: reduced awakening from sleep during hypoglycemia, *Diabetes*, 2003;52:1195–203.
- Allen KV, Frier BM, Nocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward prevention, *Endocr Pract*, 2003;9:530–43.
- Sovik O, Thordarson H, Dead-in-bed syndrome in young diabetic patients, *Diabetes Care*, 1999;22(Suppl. 2):B40–2.
- Johnson SR, Cooper MN, Davis EA, et al., Hypoglycaemia, fear of hypoglycaemia and quality of life in children with Type 1 diabetes and their parents, *Diabet Med*, 2013;30:1126–31.
- Barnard K, Thomas S, Royle P, et al., Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review, *BMC Pediatr*, 2010;10:50.
- Brazeau AS, Rabasa-Lhoret R, Strychar I, et al., Barriers to physical activity among patients with type 1 diabetes, *Diabetes Care*, 2008;31:2108–9.
- Wood JR, Miller KM, Maahs DM, et al., Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines, *Diabetes Care*, 2013;36:2035–7.
- Marzelli MJ, Mazaika PK, Barnea-Goraly N, et al., Neuroanatomical correlates of dysglycemia in young children

- with type 1 diabetes, *Diabetes*, 2014;63:343–53.
19. Weber C, Schnell O, The assessment of glycemic variability and its impact on diabetes-related complications: an overview, *Diabetes Technol Ther*, 2009;11:623–33.
  20. Johnson SR, Cooper MN, Jones TW, et al., Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study, *Diabetologia*, 2013;56:2392–400.
  21. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study G, Tamborlane WV, Beck RW, et al., Continuous glucose monitoring and intensive treatment of type 1 diabetes, *N Engl J Med*, 2008;359:1464–76.
  22. Pickup JC, Freeman SC, Sutton AJ, Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data, *BMJ*, 2011;343:d3805.
  23. Polonsky WH, Hessler D, What are the quality of life-related benefits and losses associated with real-time continuous glucose monitoring? A survey of current users, *Diabetes Technol Ther*, 2013;15:295–301.
  24. Hermanides J, DeVries JH, Sense and nonsense in sensors, *Diabetologia*, 2010;53:593–6.
  25. Battelino T, Phillip M, Bratina N, et al., Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes, *Diabetes Care*, 2011;34:795–800.
  26. Heinemann L, DeVries JH, Evidence for continuous glucose monitoring: sufficient for reimbursement?, *Diabet Med*, 2014;31:122–5.
  27. Zijlstra E, Heise T, Nosek L, et al., Continuous glucose monitoring: quality of hypoglycaemia detection, *Diabetes Obes Metab*, 2013;15:130–5.
  28. Mastroiuto J, Shin J, Marcus A, et al., The accuracy and efficacy of real-time continuous glucose monitoring sensor in patients with type 1 diabetes, *Diabetes Technol Ther*, 2008;10:385–90.
  29. Kropff J, Bruttomesso D, Doll W, et al., Accuracy of two continuous glucose monitoring systems: a head-to-head comparison under clinical research centre and daily life conditions, *Diabetes Obes Metab*, 2015;17:343–9.
  30. Matuleviciene V, Joseph JJ, Andelin M, et al., A clinical trial of the accuracy and treatment experience of the Dexcom G4 sensor (Dexcom G4 system) and Enlite sensor (guardian REAL-time system) tested simultaneously in ambulatory patients with type 1 diabetes, *Diabetes Technol Ther*, 2014;16:759–67.
  31. Damiano ER, McKeon K, El-Khatib FH, et al., A comparative effectiveness analysis of three continuous glucose monitors: the Navigator, G4 Platinum, and Enlite, *J Diabetes Sci Technol*, 2014;8:699–708.
  32. Keenan DB, Grosman B, Clark HW, et al., Continuous glucose monitoring considerations for the development of a closed-loop artificial pancreas system, *J Diabetes Sci Technol*, 2011;5:1327–36.
  33. Albisser AM, Leibl BS, Ewart TG, et al., Clinical control of diabetes by the artificial pancreas, *Diabetes*, 1974;23:397–404.
  34. Okabayashi T, Kozuki A, Sumiyoshi T, et al., Technical challenges and clinical outcomes of using a closed-loop glycemic control system in the hospital, *J Diabetes Sci Technol*, 2013;7:238–46.
  35. Dauber A, Corcia L, Safer J, et al., Closed-loop insulin therapy improves glycemic control in children aged <7 years: a randomized controlled trial, *Diabetes Care*, 2013;36:222–7.
  36. Eleri D, Allen JM, Kumareswaran K, et al., Closed-loop basal insulin delivery over 36 hours in adolescents with type 1 diabetes: randomized clinical trial, *Diabetes Care*, 2014;37:838–44.
  37. Eleri D, Allen JM, Tauschmann M, et al., Feasibility of overnight closed-loop therapy in young children with type 1 diabetes aged 3–6 years: comparison between diluted and standard insulin strength, *BMJ Open Diabetes Res Care*, 2014;2:e000040.
  38. Eleri D, Maltoni G, Allen JM, et al., Safety of closed-loop therapy during reduction or omission of meal boluses in adolescents with type 1 diabetes: a randomized clinical trial, *Diabetes Obes Metab*, 2014;16:1174–8.
  39. Hovorka R, Eleri D, Thabit H, et al., Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial, *Diabetes Care*, 2014;37:1204–11.
  40. Hovorka R, Kumareswaran K, Harris J, et al., Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies, *BMJ*, 2011;342:d1855.
  41. Phillip M, Battelino T, Atlas E, et al., Nocturnal glucose control with an artificial pancreas at a diabetes camp, *N Engl J Med*, 2013;368:824–33.
  42. Thabit H, Lubina-Solomon A, Stadler M, et al., Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study, *Lancet Diabetes Endocrinol*, 2014;2:701–9.
  43. Thabit H, Tauschmann M, Allen JM, et al., Home use of an artificial beta cell in type 1 diabetes, *N Engl J Med*, 2015;373:2129–40.
  44. Shah VN, Shoskes A, Tawfik B, et al., Closed-loop system in the management of diabetes: past, present, and future, *Diabetes Technol Ther*, 2014;16:477–90.
  45. Bergenstal RM, Klonoff DC, Garg SK, et al., Threshold-based insulin-pump interruption for reduction of hypoglycemia, *N Engl J Med*, 2013;369:224–32.
  46. NCT02463097, Hybrid closed loop pivotal trial in type 1 diabetes. Available at: <https://clinicaltrials.gov/ct2/show/NCT02463097> (accessed 10 November 2015).
  47. Beck RW, Raghinaru D, Wadwa RP, et al., Frequency of morning ketosis after overnight insulin suspension using an automated nocturnal predictive low glucose suspend system, *Diabetes Care*, 2014;37:1224–9.
  48. Buckingham BA, Cameron F, Calhoun P, et al., Outpatient safety assessment of an in-home predictive low-glucose suspend system with type 1 diabetes subjects at elevated risk of nocturnal hypoglycemia, *Diabetes Technol Ther*, 2013;15:622–7.
  49. Buckingham BA, Raghinaru D, Cameron F, et al., Predictive low-glucose insulin suspension reduces duration of nocturnal hypoglycemia in children without increasing ketosis, *Diabetes Care*, 2015;38:1197–204.
  50. Danne T, Tsioli C, Kordonouri O, et al., The PILGRIM study: in silico modeling of a predictive low glucose management system and feasibility in youth with type 1 diabetes during exercise, *Diabetes Technol Ther*, 2014;16:338–47.
  51. van Bon AC, Kohinor MJ, Hoekstra JB, et al., Patients' perception and future acceptance of an artificial pancreas, *J Diabetes Sci Technol*, 2010;4:596–602.
  52. Eleri D, Acerini CL, Allen JM, et al., Parental attitudes towards overnight closed-loop glucose control in children with type 1 diabetes, *Diabetes Technol Ther*, 2010;12:35–9.
  53. Finan DA, McCann TW Jr, Mackowiak L, et al., Closed-loop control performance of the Hypoglycemia-Hyperglycemia Minimizer (HHM) System in a feasibility study, *J Diabetes Sci Technol*, 2014;8:35–42.
  54. Finan DA, McCann TW Jr, Rhein K, et al., Effect of algorithm aggressiveness on the performance of the Hypoglycemia-Hyperglycemia Minimizer (HHM) System, *J Diabetes Sci Technol*, 2014;8:685–90.
  55. Finan DA, McCann TW, Anhalt H, et al., Hypoglycemia safeguard capabilities of the predictive Hypoglycemia-Hyperglycemia Minimizer (HHM) System. Presented at the 6th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD); Paris, France. 27 February–2 March 2013.
  56. Finan DA, Dassau E, Breton MD, et al., Sensitivity of the Predictive Hypoglycemia Minimizer System to the Algorithm Aggressiveness Factor, *J Diabetes Sci Technol*, 2015;.
  57. Hovorka R, Allen JM, Eleri D, et al., Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial, *Lancet*, 2010;375:743–51.